Non-small cell lung cancer

News

WCLC: Summit trumpets data with Keytruda challenger

MSD's PD-1 inhibitor Keytruda has ruled the immunotherapy of non-small cell lung cancer (NSCLC) for many years, but a bispecific antibody from Summit Therapeutics and partner Akeso looks li

News

Bayer takes lung cancer therapy hope into phase 3

Bayer has advanced its small-molecule drug BAY 2927088 into phase 3 for non-small cell lung cancer (NSCLC) with HER2 activating mutations, one of the drugs central to the company’s plan to

News

J&J's Rybrevant okay challenges Tagrisso in first-line NSCLC

AstraZeneca's EGFR inhibitor Tagrisso has become the go-to therapy for EGFR-mutated non-small cell lung cancer (NSCLC), but now has competition from Johnson & Johnson's Rybrevant and La

News

With FDA okay, AZ takes on MSD in early-stage lung cancer

AstraZeneca has claimed FDA approval for its immunotherapy Imfinzi before and after surgery for non-small cell lung cancer, setting up a contest with MSD's rival Keytruda.

News

ODAC unpicks AZ's Imfinzi trial in perioperative NSCLC

FDA reviewers were so frustrated by AstraZeneca's application for Imfinzi as a treatment before and after surgery for resectable non-small cell lung cancer (NSCLC) that they voted for a ret

News

Roche’s TIGIT drug linked to worse outcomes in NSCLC trial

Roche’s anti-TIGIT drug tiragolumab has failed a lung cancer study, denting enthusiasm for the programme just as there were signs that it was getting back on track after a series of disappo

WCLC: Summit trumpets data with Keytruda challenger

Bayer takes lung cancer therapy hope into phase 3

J&J's Rybrevant okay challenges Tagrisso in first-line NSCLC

With FDA okay, AZ takes on MSD in early-stage lung cancer

ODAC unpicks AZ's Imfinzi trial in perioperative NSCLC

Roche’s TIGIT drug linked to worse outcomes in NSCLC trial

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Non-small cell lung cancer

Editor's Picks